series-a
Stage
2019
Founded
2
Investors
About
Basking Biosciences develops the first reversible thrombolytic therapy for acute ischemic stroke using RNA aptamers that target von Willebrand Factor, with a complementary reversal agent to mitigate bleeding risks.
Explore Basking Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.